{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:30:50Z","timestamp":1767907850149,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Progressive multifocal leukoencephalopathy (PML) can rarely occur in Multiple Sclerosis (MS) patients undergoing dimethyl fumarate (DMF) treatment. Our case stresses the limits of current diagnostic and stratification risk criteria, highlighting the potential role of Magnetic Resonance Imaging (MRI) in advising clinical choices.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 54\u2009years old MS male patient treated with DMF, after 3 years of clinical stability developed a subacute clinical worsening. He had no severe lymphopenia but MRI signs suggestive of a coexistence of PML and MS activity. Although his viral title was negative, DMF was discontinued, with clinical and radiological improvement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case highlights the challenges behind PML diagnosis, especially in patients not fulfilling the risk stratification criteria and that might present with concurrent disease activity, stressing the potential role of MRI in informing therapeutic decisions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02165-0","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T05:02:46Z","timestamp":1617598966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions"],"prefix":"10.1186","volume":"21","author":[{"given":"Elena Augusta","family":"Vola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Petracca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-5160","authenticated-orcid":false,"given":"Sirio","family":"Cocozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Pontillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo Brescia","family":"Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"issue":"6","key":"2165_CR1","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00415-017-8509-9","volume":"264","author":"RJ Gieselbach","year":"2017","unstructured":"Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, Nieuwkamp DJ, et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol. 2017;264(6):1155\u201364. https:\/\/doi.org\/10.1007\/s00415-017-8509-9.","journal-title":"J Neurol"},{"key":"2165_CR2","unstructured":"Biogen-Medical Information TECFIDERA\u2122 (dimethyl fumarate): Progressive Multifocal Leukoencephalopathy Summary. Accessed 10 Sept 2020."},{"key":"2165_CR3","doi-asserted-by":"publisher","unstructured":"Jordan AL, Yang J, Fisher CJ, Racke MK, Mao-Draayer Y. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Mult Scler J. 2020:135245852094915. https:\/\/doi.org\/10.1177\/1352458520949158.","DOI":"10.1177\/1352458520949158"},{"issue":"15","key":"2165_CR4","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious disease section. Neurology. 2013;80(15):1430\u20138. https:\/\/doi.org\/10.1212\/WNL.0b013e31828c2fa1.","journal-title":"Neurology."},{"issue":"10","key":"2165_CR5","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/jnnp-2016-313772","volume":"87","author":"MT Wijburg","year":"2016","unstructured":"Wijburg MT, Witte BI, Vennegoor A, Roosendaal SD, Sanchez E, Liu Y, et al. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosurg Psychiatry. 2016;87(10):1138\u201345. https:\/\/doi.org\/10.1136\/jnnp-2016-313772.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2165_CR6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fneur.2017.00294","volume":"8","author":"G Pontillo","year":"2017","unstructured":"Pontillo G, Cocozza S, Lanzillo R, Borrelli P, de Rosa A, Brescia Morra V, et al. Brain susceptibility changes in a patient with Natalizumab-related progressive multifocal Leukoencephalopathy: a longitudinal quantitative susceptibility mapping and Relaxometry study. Front Neurol. 2017;8:294. https:\/\/doi.org\/10.3389\/fneur.2017.00294.","journal-title":"Front Neurol"},{"issue":"6","key":"2165_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000171","volume":"2","author":"T Sinnecker","year":"2015","unstructured":"Sinnecker T, Othman J, Kuhl M, et al. 7T MRI in natalizumab-associated PML and ongoing MS disease activity: a case study. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e171. https:\/\/doi.org\/10.1212\/NXI.0000000000000171.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2165_CR8","first-page":"643216","volume":"2015","author":"MA Babi","year":"2015","unstructured":"Babi MA, Pendlebury W, Braff S, Waheed W. JC virus PCR detection is not infallible: a fulminant case of progressive multifocal Leukoencephalopathy with false-negative cerebrospinal fluid studies despite progressive clinical course and radiological findings. Case Rep Neurol Med. 2015;2015:643216.","journal-title":"Case Rep Neurol Med"},{"issue":"3","key":"2165_CR9","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1148\/radiol.2015150673","volume":"278","author":"J Hodel","year":"2016","unstructured":"Hodel J, Outteryck O, Dubron C, Dutouquet B, Benadjaoud MA, Duhin E, et al. Asymptomatic progressive multifocal Leukoencephalopathy associated with Natalizumab: diagnostic precision with MR imaging. Radiology. 2016;278(3):863\u201372. https:\/\/doi.org\/10.1148\/radiol.2015150673.","journal-title":"Radiology."},{"key":"2165_CR10","doi-asserted-by":"publisher","first-page":"232470962093980","DOI":"10.1177\/2324709620939802","volume":"8","author":"SF De Mercanti","year":"2020","unstructured":"De Mercanti SF, Gned D, Matta M, Iudicello M, Franchin E, Clerico M. Atypical multiple sclerosis lesions or progressive multifocal Leukoencephalopathy lesions: that is the question. J Invest Med High Impact Case Rep. 2020;8:2324709620939802. https:\/\/doi.org\/10.1177\/2324709620939802.","journal-title":"J Invest Med High Impact Case Rep"},{"issue":"1-2","key":"2165_CR11","first-page":"33","volume":"15","author":"C Mullins","year":"2018","unstructured":"Mullins C, Miranda J, Sandoval H, Ramos-Duran L, Tonarelli SB. The benefit of mirtazapine in the treatment of progressive multifocal Leukoencephalopathy in a young HIV-positive patient: a case report. Innov Clin Neurosci. 2018;15(1-2):33\u20135.","journal-title":"Innov Clin Neurosci"},{"issue":"10","key":"2165_CR12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40261-016-0433-8","volume":"36","author":"Y Jamilloux","year":"2016","unstructured":"Jamilloux Y, Kerever S, Ferry T, Broussolle C, Honnorat J, S\u00e8ve P. Treatment of progressive multifocal Leukoencephalopathy with mirtazapine. Clin Drug Invest. 2016;36(10):783\u20139. https:\/\/doi.org\/10.1007\/s40261-016-0433-8.","journal-title":"Clin Drug Invest"},{"issue":"5700","key":"2165_CR13","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1126\/science.1103492","volume":"306","author":"GF Elphick","year":"2004","unstructured":"Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306(5700):1380\u20133. https:\/\/doi.org\/10.1126\/science.1103492.","journal-title":"Science."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02165-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-021-02165-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02165-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T17:03:04Z","timestamp":1617642184000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02165-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2165"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02165-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"16 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study formal consent is not applicable; written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest and no disclosures relevant to the manuscript.S.C. reports fees for speaking from Sanofi and Amicus.M.P. reports travel sponsorship from Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}